Abstract:Iodine-131‑labeled monoiodohypericin (131I‑Hyp) is a necrosis avid compound used as a complementary anticancer agent. Herein, the biodistribution in rats with re-perfused partial liver infarction (RPLI) was used to estimate its human internal radiation dosimetry. Iodine-123‑labeled monoiodohypericin (123I-Hyp) as a safer surrogate for 131I-Hyp was prepared with iodogen as oxidant. Determination of radiochemical yield and purification was performed by high performance liquid chromatography (HPLC). To control aggregation, the formulation was macroscopically and microscopically examined. Biodistribution of 123I-Hyp was studied in RPLI rats (n=18) at 4, 24 and 48 h post-injection. Tissue gamma counting (TGC), autoradiography and histology were performed. Dosimetry of 131I-Hyp in hepatic necrosis and in normal human organs was estimated using biodistribution data of 123I-Hyp, the Organ Level Internal Dose Assessment/Exponential Modeling (OLINDA/EXM®), a sphere model and male and female phantoms. A radiochemical yield of 95% was achieved in labeling of 123I-Hyp with a radiochemical purity of 99% after HPLC purification. In the Hyp added formulation, no macroscopic but minimal microscopic aggregation was observed. By TGC, selective accumulation in hepatic infarction and low uptake in viable liver of 123I‑Hyp/Hyp were detected, as confirmed by autoradiography and histology. Significantly higher doses of 131I-Hyp were delivered to necrotic (276‑93,600 mGy/MBq) than to viable (4.2 mGy/MBq) liver (P<0.05). In normal organs, 123I‑Hyp was eliminated within 24 h except for relatively high levels in the lungs and thyroid. Hepatobiliary elimination was a major pathway of 123I-Hyp causing high activity in the intestines. For both genders, dosimetry showed the longest residence time of 131I-Hyp in the remainder, followed by the lungs, intestines and thyroid. The highest absorbed radiation dose was seen in necrotic tissues and the shortest residence times and lowest absorbed radiation dose were found in the brain. 131I-Hyp selectively delivers higher radiation dose to necrosis compared with the rest of the body. Among normal organs, thyroids, lungs and intestines receive considerable radiation dose, which deserves cautious attention in developing this anticancer approach.

Synthesis of radioiodinated carnosine for hepatotoxicity imaging induced by carbon tetrachloride and its biological assessment in rats

Assessment of Radiolabeled L-Carnitine for Hepatotoxicity Imaging in Rats

Preliminary Studies of a Novel Cyclopentadienyl Tricarbonyl Technetium-99M Fatty Acid Derivative for Myocardical Imaging.

Synthesis of 99mTc-aroylhydrazinocarbonylmethyliminodiacetic acids and their animal study, hepatobiliary pharmaceuticals

Synthesis and preclinical evaluation of a 89Zr-labelled human single chain antibody for non-invasive detection of hepatic myofibroblasts in acute liver injury

Synthesis and Biodistribution of the 99m Tc Nitrido Complex with 2-(4-nitro-1h-imidazolyl)ethyl Dithiocarbamate (NIET)

Sodium cholate, a solubilizing agent for the necrosis avid radioiodinated hypericin in rabbits with acute myocardial infarction

Synthesis of Labelled Small Peptide Complexes for Imaging Agents with Technetium-99M and Biodistribution in Mice.

An Experimental Study on Mice Bearing Liver Cancer Imaging with ~(99)Tc~m-Hl91

Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma

Synthesis and Bioevaluation of Radioiodated Nitroimidazole-Based Hypoxia Imaging Agents Containing Different Charged Substituents

Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic

Preclinical Study of 68Ga-DOTATOC: Biodistribution Assessment in Syrian Rats and Evaluation of Absorbed Dose in Human Organs

Radioiodination, biodistribution and pharmacokinetics of berberine in mice

Targetability and biodistribution of radioiodinated hypericin: comparison between microdosing and carrier-added preparations

Synthesis and Biodistribution of 99Mtc-Carbonyltechnetium-labeled Fatty Acids

Biological Evaluation of [18F]AlF-NOTA-NSC-GLU as a Positron Emission Tomography Tracer for Hepatocellular Carcinoma

Long-term biological effects after acute 131I-administration of two rat models (with and without thyroid)

Microfluidic controllable preparation of iodine‐131‐labeled microspheres for radioembolization therapy of liver tumors

Chelator-Free Labeling of Layered Double Hydroxide Nanoparticles for in Vivo PET Imaging

Iota carrageenan linked barium ion nanoparticle synthesis for the selective targeted imaging and inhibition of cancer cells